| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | IDE397 MTAP-deleted NSCLC | Phase 1/2 | — | - | - | ||
Phase 1/2 data readout example | IDE397 MTAP-deleted NSCLC | Phase 1/2 | — | - | - | ||
Phase 1/2 data readout example | IDE397 MTAP-deleted NSCLC | Phase 1/2 | — | - | - |
Recent Updates
Recently added Catalysts
IDEAYA Biosciences, Inc.$28.98
+0.14 (+0.49%)
C 52Pipeline Score Overvalued Pharma · Commercial
Market Cap
2.56 B
EPS
-1.58
P/E Ratio
-
Value Trade
30.21 M
SEC Financials
Q1 2026Dilution Risk
Revenue
6.56 M
R&D Expenses
95.73 M
Operating CF
-75.17 M
Total Assets
1.03 B
Total Liabilities
93.08 M
Equity
937.27 M
D/E Ratio
12,345
1.78 %
Week
-8.58 %
1 Month
-11.55 %
3 Month
-12.4 %
6 Month
43 %
5 Year
107.86 %
All Time
Cash Data
Cash Position
671.20 M
Monthly Burn
25.06 M
Runway
25.6 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
617.37 K
52 Week Range
18.77 - 39.28
% held by Insiders
5.45 %
% held by Institutions
104.77 %
Enterprise Value
1.91 B
Total Shares
87.87 M
Short %
13.02 %
Float Shares
87.08 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C52
Pipeline Score $768M
Pipeline ValueOvervalued
Valuation Signal8
Drugs Scored0.3x
rNPV / MCap Top 81%
Small Cap (rank 173 of 905)
Percentile RankIDEAYA Biosciences, Inc. carries a moderate pipeline score (52/100), with $1.2B risk-adjusted pipeline value, led by IDE-161 in Advanced or Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDE-161 Small molecule | Advanced or Metastatic Solid Tumors | Phase 1 | NCT05787587 | 5% | $941M | ACTIVE NOT_RECRUITING | 216 | FAST | C (45) | May 1, 2027 | MODERATE_RISK | MEDIUM Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
darovasertib | metastatic uveal melanoma | Phase 2/3 | 2025-08-05 | |||
darovasertib | metastatic uveal melanoma | Phase 2/3 | 2025-08-05 | |||
darovasertib | metastatic uveal melanoma | Phase 2/3 | 2025-08-05 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IDYA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IDYA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IDYA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IDYA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IDYA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
IDYA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-06-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest IDEAYA Biosciences, Inc. (IDYA) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How IDYA ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Melanoma | #5 of 52 | Darovasertib | MRK BMY REGN | $10.5B | 0.83 | ||
| Mesothelioma | #8 of 15 | IDE892 + IDE397 | AZN MRK NVS | $0.65B | 0.76 | ||
| Esophageal Cancer | #16 of 39 | IDE892 + IDE397 | AZN MRK ONC | $1.85B | 0.76 | ||
| Prostate Cancer | #18 of 53 | IDE-161 + Pembrolizumab | MRK AZN PFE | $25.12B | 0.89 | ||
| Endometrial Cancer | #18 of 46 | IDE-161 + Pembrolizumab | MRK AZN GILD | $31.09B | 0.89 | ||
| Head and Neck Cancer | #25 of 62 | IDE-161 + Pembrolizumab | AZN GSK JNJ | $10.2B | 0.89 | ||
| Ovarian Cancer | #26 of 60 | IDE-161 + Pembrolizumab | MRK AZN LLY | $4.11B | 0.89 | ||
| Bladder Cancer | #28 of 47 | IDE892 + IDE397 | AZN BMY JNJ | $0.33B | 0.76 | ||
| Gastric Cancer | #28 of 49 | IDE892 + IDE397 | AZN ONC JAZZ | $6.74B | 0.76 | ||
| Breast Cancer | #30 of 94 | IDE-161 + Pembrolizumab | AZN MRK LLY | $10.85B | 0.89 | ||
| Colorectal Cancer | #31 of 82 | IDE-161 + Pembrolizumab | ABBV BMY MRK | $7.68B | 0.87 | ||
| Non-Small Cell Lung Cancer | #36 of 88 | IDE-161 + Pembrolizumab | MRK AZN RVMD | $28.1B | 0.83 | ||
| Lung Cancer | #36 of 78 | IDE-161 + Pembrolizumab | MRK GILD AMGN | $28.1B | 0.78 |